Drug
Valrubicin
Valrubicin: highest development phase Phase 2/3, developed by Endo, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Endo, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Valrubicin, 800 mg NCT01316874 | Phase 2/3 | Carcinoma in Situ |
| Valrubicin NCT01606345 | Phase 1 | Urothelial Carcinoma |
Latest
No recent events.
Follow Valrubicin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.